Insulin Glargine (Lantus) Injectable Suppliers & Bulk Manufacturers
Available Forms: Vials/pens
Available Strengths: U-100, U-300
Reference Brands: Lantus, Basaglar, Toujeo(US); Lantus, Toujeo(EU)
Category: Diabetes
Insulin Glargine (Lantus) provides a steady, long-lasting release of insulin, mimicking natural basal insulin to regulate blood sugar levels throughout the day. Its benefits include consistent glucose control, reduced risk of hypoglycemia, and improved insulin adherence, making it effective for managing both type 1 and type 2 diabetes. Insulin Glargine (Lantus) injectable is available in Vials/pens and strengths such as U-100, U-300. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Insulin Glargine (Lantus) injectable is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Insulin Glargine (Lantus) injectable can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
Product Description:
Insulin Glargine (Lantus) is a long-acting basal insulin approved in the EU and US for managing diabetes. In the EU, it is regulated by the EMA, with Sanofi’s Lantus and Toujeo holding approved dossiers demonstrating safety and efficacy. In the US, the FDA approved Lantus and biosimilars like Basaglar, based on comprehensive clinical data and biosimilarity studies. Both regions require detailed dossiers and ongoing pharmacovigilance for post-marketing surveillance. For expert support with regulatory dossiers and compliance, visit PharmaTradz, your trusted partner in pharmaceutical regulatory services.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Insulin Glargine is a synthetic human insulin analogue produced by recombinant DNA technology using Escherichia coli or Saccharomyces cerevisiae (yeast) cells. The amino acid sequence is modified to provide prolonged, consistent insulin release after injection.
The main trade name of Insulin Glargine is Lantus®.
Other marketed brand names include
The original manufacturer of Lantus® is Sanofi-Aventis.
Other companies manufacturing biosimilar versions include
The generic name is Insulin Glargine.
The brand name is Lantus® (by Sanofi).
Common biosimilar brand names:
Lantus® is manufactured by Sanofi-Aventis at multiple global facilities, including sites in Frankfurt (Germany), Paris (France), and India (Sanofi India Ltd., Goa).
Biosimilars are also manufactured in the
Related Products
Pioglitazone Hydrochloride
Strength:
15 mg, 30 mg, 45 mg
Form: Tablets
Reference Brands: Actos (USA)
View Details
Nateglinide
Strength:
60 mg, 120 mg, 180 mg
Form: Tablets
Reference Brands: Starlix (USA)
View Details
Miglitol
Strength:
25 mg, 50 mg, 100 mg
Form: Tablets
Reference Brands: Glyset (USA), Diastabol (EU)
View Details
Sotagliflozin
Strength:
200 mg, 40mg
Form: Tablets
Reference Brands: Inpefa (USA), Zynquista (EU)
View DetailsQuick Response Guaranteed | Verified Suppliers
